Saturday, July 11, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “placebo” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 588
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 588 pipeline programs matching "placebo" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

588 results for “placebo” Back to intelligence hub

Search results

Page 11 of 25
  1. placebo (saline)

    Sanofi Pasteur

    Sphingomyelin Lipidosis

    phase 3 small molecule completed

    1 trial
  2. placebo for risankizumab

    AbbVie

    Crohn's Disease

    phase 3 small molecule completed

    1 trial
  3. placebo for risankizumab IV

    AbbVie

    Crohn's Disease

    phase 3 small molecule completed

    1 trial
  4. placebo plus docetaxel

    Boehringer Ingelheim

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial
  5. placebo to match albiglutide

    GlaxoSmithKline

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial
  6. xevinapant, Xevinapant Placebo

    Merck Sharp and Dohme

    Resected squamous cell carcinoma of the head and neck

    phase 3 small molecule active

    1 trial
  7. ziltivekimab, Placebo (ziltivekimab C)

    NovoThirteen

    Heart failure with mildly reduced or preserved ejection fraction and systemic inflammation

    phase 3 small molecule active

    1 trial
  8. (+)-α-DIHYDROTETRABENAZINE, ADE513 placebo

    Lacuna Pharma Pty Ltd

    Tardive dyskinesia

    phase 2 small molecule active

    1 trial
  9. 01-02-TL-375-015

    Takeda

    Drug Abuse

    phase 2 small molecule completed

    1 trial
  10. 6QC-ICG, Placebo for 6QC-ICG

    Disc Medicine

    Breast cancer

    phase 2 small molecule active

    1 trial
  11. ACT-1004-1239 matching placebo

    Lacuna Pharma Pty Ltd

    Progressive multiple sclerosis (MS)

    phase 2 small molecule active

    1 trial
  12. ALXN 2040, Placebo matching ALXN2040

    Alexion Europe SAS

    Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD)

    phase 2 small molecule active

    1 trial
  13. ALXN 2050, ALXN2050 Placebo Tablets

    Alexion Europe SAS

    Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)

    phase 2 small molecule active

    1 trial
  14. AMG 133, Placebo for AMG 133

    Amgen

    Overweight and Obesity

    phase 2 small molecule active

    1 trial
  15. AP707, Placebo

    Lacuna Pharma Pty Ltd

    Borderline personality disorder

    phase 2 small molecule active

    1 trial
  16. APG777, Placebo

    Apogee Therapeutics

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial
  17. ATI-045, Placebo to ATI-045

    Aclaris Therapeutics

    Atopic dermatitis

    phase 2 small molecule active

    1 trial
  18. AXATILIMAB, Placebo

    Syndax Pharmaceuticals

    Idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial
  19. AZD0292, Placebo for AZD0292

    AstraZeneca AB

    Bronchiectasis with chronic pseudomonas aeruginosa colonization

    phase 2 small molecule active

    1 trial
  20. AZD1163 Placebo, AZD1163

    AstraZeneca AB

    Rheumatoid arthritis

    phase 2 small molecule active

    1 trial
  21. AZD7798 Placebo, AZD7798

    AstraZeneca AB

    Crohn's Disease

    phase 2 small molecule active

    1 trial
  22. Aleniglipron or Placebo

    Structure Therapeutics

    Obesity, Overweight, or Chronic Weight Management

    phase 2 small molecule active

    2 trials
  23. Alxn1920 placebo product, ALXN1920

    Alexion Europe SAS

    Primary Mebranous Nephropathy (PMN)

    phase 2 small molecule active

    1 trial
  24. Amlitelimab, Placebo

    Sanofi-aventis Healthcare Pty Ltd

    Asthma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.